Royalty Pharma plc RPRX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry's leading therapies, which includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Biogen's Tysabri and Spinraza, Roche's Evrysdi, Astellas and Pfizer's Xtandi, Johnson & Johnson's Tremfya, AbbVie and Johnson & Johnson's Imbruvica, Servier's Voranigo, Gilead's Trodelvy, Amgen's Imdelltra and Alnylam's Amvuttra, among others, and 20 development-stage product candidates.

Last close 63.86 2026-10-23
Market cap $28.42B estimated share count
52-week range 35.91 - 64.38

Valuation FY2025 figures against the last close

P/S12.0x
P/E35.9x
P/FCF11.4x
EV/EBITDA23.5x
Dividend yield—
Diluted EPS1.78

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $2.38B$2.26B$2.35B$2.24B$2.29B$2.12B$1.81B$1.79B—
R&D $452.0M$2.0M$52.0M$177.1M$200.1M$26.3M$83.0M$392.6M—
SG&A $573.5M$236.7M$249.7M$227.3M$182.8M$181.7M$103.4M$61.9M—
Total operating expenses $818.7M$971.1M$862.4M$1.93B$858.7M$527.0M-$808.9M$430.4M—
Operating income $1.56B$1.29B$1.49B$307.1M$1.43B$1.60B$2.62B$1.36B—
Interest expense $307.7M$225.5M$187.2M$188.0M$166.1M$157.1M$268.6M$280.0M—
Pre-tax income $1.32B$1.33B$1.70B$230.1M$1.24B$1.70B$2.46B$1.52B—
Income tax $0$0$0$0$0$0$0$0—
Net income $1.32B$1.33B$1.70B$230.0M$1.24B$975.0M$2.35B$1.38B—
EPS, basic 1.791.922.540.101.491.32———
EPS, diluted 1.781.912.530.101.491.32———
Shares, diluted (wtd. avg.) 564.5M594.1M602.9M438.0M414.8M375.5M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $618.7M$929.0M$477.0M$1.71B$1.54B$1.01B$246.2M$1.92B$1.38B
Short-term investments $18.8M$58.2M$18.3M$1.3M$66.0M$70.0M$0——
Total current assets $1.53B$1.80B$1.27B$2.55B$2.88B$2.70B$832.1M——
Goodwill $924.6M$0———————
Other intangibles ———$0$5.7M$28.7M$51.7M——
Total assets $19.62B$18.22B$16.38B$16.81B$17.52B$16.02B$12.45B——
Accounts payable $19.4M$13.4M$15.2M$7.9M$5.6M$10.8M$11.2M——
Short-term debt $380.0M$997.8M$0$997.5M$0$0$282.0M——
Total current liabilities $636.2M$1.25B$161.4M$1.17B$171.2M$307.9M$333.4M——
Long-term debt $8.57B$6.61B$6.14B$6.12B$7.10B$5.82B$5.96B——
Total liabilities $9.91B$7.88B$6.30B$7.29B$7.27B$6.12B$6.31B——
Retained earnings $2.36B$2.85B$2.52B$1.96B$2.26B$1.92B$2.83B——
Total equity $9.71B$10.34B$10.08B$9.53B$10.25B$9.90B$6.14B$4.55B$4.46B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $2.49B$2.77B$2.99B$2.14B$2.02B$2.03B$1.67B$1.62B—
Depreciation and amortisation $3.9M$0$0——————
Stock-based compensation $289.9M$2.3M$2.4M$2.2M$2.4M$5.4M$0$0—
Investing cash flow -$1.61B-$2.68B-$2.07B-$1.03B-$1.87B-$2.76B-$2.15B$303.4M—
Financing cash flow -$1.19B$361.1M-$2.15B-$944.9M$385.1M$1.49B-$1.19B-$1.38B—
Buybacks $1.23B$229.7M$304.8M$0$0$0$4.3M$0—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-014239.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 1B 2B 3B Revenue, FY2018: 1.8B Net income, FY2018: 1.4B Revenue, FY2019: 1.8B Net income, FY2019: 2.3B Revenue, FY2020: 2.1B Net income, FY2020: 975M Revenue, FY2021: 2.3B Net income, FY2021: 1.2B Revenue, FY2022: 2.2B Net income, FY2022: 230M Revenue, FY2023: 2.4B Net income, FY2023: 1.7B Revenue, FY2024: 2.3B Net income, FY2024: 1.3B Revenue, FY2025: 2.4B Net income, FY2025: 1.3B FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $1.79B $1.81B $2.12B $2.29B $2.24B $2.35B $2.26B $2.38B
Gross profit — — — — — — — — —
Net income — $1.38B $2.35B $975.0M $1.24B $230.0M $1.70B $1.33B $1.32B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Material agreement signed Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%